by Roman Fabbricatore
Fertility and sexual health services appear to be offered to cancer survivors less often than other services at CoC-accredited practices.
Enforcing survivorship standards may help centers provide services to address the needs of cancer survivors, according to … Read more
by Linda Wang
Physical activity can have many benefits for cancer survivors, from improving their quality of life to potentially making it less likely that their disease will come back. Yet studies have shown that many cancer survivors struggle to … Read more
—No difference in adverse events, clinical benefit, OS for patients with or without waivers
by Charles Bankhead
Patients who received protocol waivers in a clinical trial of targeted anticancer therapy had outcomes similar to those who met all enrollment criteria, a large retrospective review showed.
Patients who received waivers had a clinical benefit rate … Read more
Clearity’s Perspective: This article is written by a daughter whose mother was diagnosed with advanced ovarian cancer. She shares the story of her mother’s diagnosis and treatment and how her family handled learning of her mother’s inheritable genetic condition. Clearity
As presented at the ESMO Gynaecological Cancers Congress 2024 (Florence, 20–22 June), a post-hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial in patients with high folate receptor alpha (FRalpha), platinum-resistant ovarian cancer revealed that even those who required … Read more
By Sharon Worcester, MA
CHICAGO — Carlos, a 21-year-old, lay in a hospital bed, barely clinging to life. Following a stem cell transplant for leukemia, Carlos had developed a life-threatening case of graft-vs-host disease.
But Carlos’ mother had faith.
“I … Read more
Clearity’s Perspective: This article highlights that some people with ovarian cancer who live in certain geographic locations, like rural areas, may get treated at centers with less experience treating ovarian cancer and/or fewer resources to support whole-person needs. Clearity offers … Read more
by Wayne Kuznar
CHICAGO — Clinical activity and survival outcomes improved with the addition of ipilimumab (Yervoy) to nivolumab (Opdivo) in patients with ovarian or other gynecologic clear cell carcinomas, according to results from the non-comparative phase II BrUOG 354 … Read more
by Silas Inman
The addition of atezolizumab (Tecentriq) to single-agent non–platinum-based chemotherapy and bevacizumab (Avastin) did not provide any additional benefits for patients with recurrent ovarian cancer, according to the final analysis of the phase 3 AGO-OVAR 2.29/ENGOT-ov34 study (NCT03353831) … Read more
by The ASCO Post Staff
Some people with advanced epithelial ovarian cancer may safely avoid having their lymph nodes removed during surgery without it impacting their survival outcomes, helping to reduce the risk of postoperative complications. This research was presented … Read more
by Aaron Tallent
Key Points:
Led by Dr Melissa Merritt and Dr Nicola Meagher from the Daffodil Centre … Read more
by Van Andel Research Institute
Two types of endometriosis-related ovarian cancer arise from the same cells but likely at different stages of the menstrual cycle—a nuance that significantly influences treatment response, reports a recent study led by Van Andel Institute … Read more
by Ariana Pelosci
Results of a recent study published in the Journal of Clinical Oncology highlighted the association of ovarian cancer with talcum powder (talc) use.1 The findings were from an extensive analysis of the Sister Study cohort.… Read more
Clearity offers emotional support to individuals with ovarian cancer through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our team of OC Counselors may be … Read more
by Cynthia McCormick Hibbert
For too many cancer survivors, life after treatment is fraught with a decline in cognitive function known as “chemo brain.”
A newly published study by a Northeastern professor says that yoga might hold the key to … Read more
by Edward Winstead
This story has an accompanying Q&A with Dr. Gwendolyn Quinn, Ph.D., of the New York University Perlmutter Cancer Center, on some of the challenges faced by LGBTQ+ people with cancer and ways to address them.
After surgery … Read more
by Sabrina Serani
The FDA announced new guidance to expand eligibility criteria with the goal of improving participation and diversity in oncology clinical trials.These 3 areas of change include laboratory values, washout periods, and performance status.
While the FDA notes … Read more
by Josh Friedman
An artificial intelligence-driven algorithm used a novel liquid biopsy assay to differentiate women with ovarian … Read more
— About half of patients responded, duration of response as long as 19 months in three trials
By Charles Bankhead
The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid cancers.
The action represents the first tumor-agnostic approval for an antibody-drug conjugate targeting HER2-positive tumors. According … Read more
